RTW Investments, LP, is New York-based investment firm that focuses on companies developing transformational therapies and technologies in science and medicine. RTW has significant expertise in targeted areas of innovation and has undertaken a rigorous and comprehensive approach to researching and supporting emerging innovations in both industry and academia.

Learn More


Originally established as the venture capital arm of the Rockefeller family in 1969, Venrock partners with entrepreneurs to build some of the world’s most disruptive, successful companies. With a primary focus on technology and healthcare, portfolio companies have included Apple Computer, AveXis, Centocor, Check Point Software, Dollar Shave Club, DoubleClick, Gilead Sciences, Idec Pharma, Illumina, Intel, Juno Therapeutics, Millennium Pharma and Nest. Follow the firm on Twitter at @venrock.

Learn More


Boxer Capital LLC is a private investment firm founded by the life sciences team at Tavistock Group in 2005. Boxer Capital invents and invests in biotechnology companies that aim to drastically improve medicine. At Boxer Capital, we leverage our internal expertise in evaluating pre-clinical and clinical data to generate outsized returns for company founders and employees as well for our investor the Tavistock Group. Boxer Capital maintains a portfolio of public and private companies and has a focus on biotechnology drug development companies across multiple therapeutic indications.

Learn More

Novo Holdings

Novo Holdings is a private Danish limited liability company wholly owned by the Novo Nordisk Foundation. The company is the holding company in the Novo Group, comprising Novo Nordisk A/S, Novozymes A/S and NNIT A/S, and is responsible for managing the Foundation’s assets. In addition to being the major shareholder in the Novo Group companies, Novo Holdings provides seed and venture capital to development-stage companies, takes significant ownership positions in well-established companies within life science and manages a broad portfolio of financial assets.

Learn More

Forbion Capital Partners

Forbion Capital Partners is a dedicated life sciences venture capital firm with offices in The Netherlands and Germany. Forbion invests in life sciences companies across the pharmaceutical as well as the medical device space. It’s investment team has built an impressive performance track record since the late nineties with successful investments in over 60 companies. Forbion manages well over EUR 750M (USD 850M) across nine funds. Its investors include the EIF, through its European Recovery Programme (ERP), LfA and Dutch Venture Initiative (DVI) facilities and the KFW through the ERP – Venture Capital Fondsfinanzierung facility. Forbion also has a partnership with BioGeneration Ventures, who manage three separate seed and early stage funds focused on the BeNeLux.

Learn More

Tekla Capital Management LLC

Tekla Capital Management LLC is a registered investment adviser based in Boston, Massachusetts and is the investment adviser for four closed-end funds, Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund. The Funds predominately invest in the securities of public and private healthcare companies.

Learn More

Domain Associates

Founded in 1985, Domain was one of the first venture capital firms to exclusively invest in the life sciences sector. Domain has been involved in the formation of more than 250 companies. Today, with more than $2.7 billion in capital raised, Domain is a proven healthcare venture capital leader with solid investment returns from companies built to advance human health.

Learn More

Pappas Ventures

Established in 1994, Pappas Ventures invests exclusively in the life sciences sector – biotechnology, biopharmaceuticals, drug delivery, medical devices and related ventures – across the United States and Canada. Pappas Ventures has more than $350 million in capital under management and has guided the launch and/or development of more than 57 companies. Recent portfolio highlights include the IPOs of CoLucid Pharmaceuticals, Inc., Ultragenyx Pharmaceuticals, Inc. and Chimerix, Inc., and the acquisition of Lumena Pharmaceuticals, Inc. by Shire, plc.

Learn More
BDC logo

BDC Capital

A subsidiary of the Business Development Bank of Canada (BDC), BDC Capital offers a full spectrum of specialized financing and investment solutions to help Canadian entrepreneurs achieve their full growth potential. With more than $1 billion under management, BDC Capital takes a strategic, patient approach to nurture companies’ development over the long term.

BDC Capital’s Healthcare Venture Fund invests in transformative Canadian companies that will dramatically increase healthcare productivity by reducing healthcare costs while improving patient health. The experienced team manages $270 million in capital across two different funds.

Learn More

GO Capital, L.P.

GO Capital LP is a $50 million venture capital fund that invests in Quebec seed-stage technology firms in the fields of cleantech, information technologies and life sciences. GO Capital is managed by its General Partner, the Business Development Bank of Canada.

Learn More

Fonds de solidarité FTQ

The Fonds de solidarité FTQ helps drive Quebec’s economy. With net assets of $7.7 billion as of November 30, 2010, the Fund is a development capital investment fund that channels the savings of Quebecers into investments in all sectors of the economy to help further Quebec’s economic growth. The Fund is a partner, either directly or through its network members, in 2,052 companies. With its 577,511 owner-shareholders, it has helped, on its own or with other financial partners, to create, maintain and protect 150,133 jobs.

Learn More

iNovia Capital

iNovia Capital is a venture capital firm that partners with exceptional entrepreneurs to build successful technology companies in high-growth sectors. The team is comprised of founders, builders and engineers that are passionate about building market-leading technology companies. iNovia has $275M under management across three seed and early-stage funds. For more information, follow the firm on Twitter at @inovia.

Learn More